Health
Researchers develop ACE2 decoy to neutralise SARS-CoV-2 – Drug Target Review
Researchers have engineered human angiotensin converting enzyme 2 (hACE2) protein decoys that can protect cells from SARS-CoV-2.
Posted: 10 November 2020 | Hannah Balfour (Drug Target Review) | No comments yet
Using their de novo protein design strategy, researchers engineered human angiotensin converting enzyme 2 (hACE2) protein decoys that can protect cells from SARS-CoV-2 infection.
To infect cells within the respiratory tract, the Spike (S) protein on the surface of SARS-CoV-2 must bind to a receptor on human cells called angiotensin converting enzyme 2 (ACE2). The receptor binding domains (RBDs) are the section of the…
-
Noosa News17 hours agoChild, 15, arrested over death of another child, 8, after shocking e-bike crash in Queensland
-
General15 hours agoCrowe toasts talkback titan for platforming ‘voiceless’
-
Business18 hours agoSolid superannuation gains continue to roll in
-
General9 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate